E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Uncomplicated respiratory tract infections in children. |
Infecciones respiratorias no complicadas en niños. |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory tract infections |
Infecciones respiratorias |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate whether a delayed antibiotic prescription strategy compared with traditional antibiotic prescription or no antibiotic prescription leads to a similar duration in the severity of symptoms in children with uncomplicated respiratory tract infections. |
Determinar el efecto de las diferentes estrategias de tratamiento antibiótico sobre la duración y gravedad de los síntomas en las infecciones respiratorias agudas no complicadas en pacientes pediátricos. |
|
E.2.2 | Secondary objectives of the trial |
Determinate the impact of the different treatment strategies/ Perceptions and attitudes about these treatment strategies/ The cost-effectiveness of the strategies/The number of additional medical visits/ The safety. |
Determinar el impacto de las diferentes estrategias de tratamiento/ Las percepciones y actitudes acerca de estas estrategias de tratamiento/ El coste-efectividad de las estrategias/ El número adicional de las visitas médicas/La seguridad. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
I) Children, up to 14 years, with uncomplicated respiratory infections: acute otitis media, rhinosinusitis, pharyngotonsillitis and acute bronchitis. II) To have reasonable doubts of the antibiotic prescription. |
I) Niños hasta los 14 años con infecciones respiratorias no complicadas: otitis media aguda, rinosinusitis, faringoamigdalitis y bronquitis aguda. II) Con dudas razonables de la necesidad de prescripción antibiótica. |
|
E.4 | Principal exclusion criteria |
I) Patients greater than or equal to 15 years of age. II) To be certain of the antibiotic prescription III) Pediatric patient with symptoms or signs suggestive of a serious condition and/or complications. |
I) Pacientes mayores o igual a 15 años de edad. II) Tener la certeza de la necesidad de prescripción antibiótica III) Pacientes pediátricos con síntomas o signos sugestivos de una enfermedad grave y / o complicaciones. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Duration and severity of symptoms |
Duración y severidad de los síntomas |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
I) Antibiotic consumption II) Parents? satisfaction III) Parents' and pediatricians? belief in the efficacy of antibiotics IV) Perception of safety and efficacy V) Complications related to the infection process. |
I) Consumo de antibióticos II) Satisfacción de los padres III) Creencias de los pediatras y padres de los pacientes en la eficacia de los antibióticos IV) La percepción de la seguridad y la eficacia V) Complicaciones relacionadas con el proceso de infección. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
30 days and after one year. |
30 días y al cabo de 1 año. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
no antibióticos |
no antibiotics |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
1 year after the last visit |
1 año después de la última visita |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |